Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib

Oncology

Volumn 77, Issue 5, 2009, Pages 257-271

  Lipworth, Adam D ^a   Robert, Caroline ^b   Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Acral erythema; Burgdorf reaction; Hand foot skin reaction; Hand foot syndrome; Multireceptor tyrosine kinase inhibitors; Palmar plantar erythrodysesthesia; Sorafenib; Sunitinib; Toxic erythema

Indexed keywords

ALPHA TOCOPHEROL; ALPHA2 INTERFERON; AMIFOSTINE; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOXORUBICIN; EMOLLIENT AGENT; ERLOTINIB; FLUOROURACIL; HENNA; INTERFERON; KERATOLYTIC AGENT; NICOTINE PATCH; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; QUINOLONE DERIVATIVE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG;

ADD ON THERAPY; CHEILITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; DYSESTHESIA; FACE ERYTHEMA; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY CANCER; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SKIN MANIFESTATION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; ERYTHEMA; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INDOLES; PARESTHESIA; PROGNOSIS; PYRIDINES; PYRROLES; RISK FACTORS; SYNDROME;

EID: 70449647041     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258880     Document Type: Review

References (119)

1. Zuehlke RL: Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148: 90-92.
2. Burgdorf WH, Gilmore WA, Ganick RG: Peculiar acral erythema secondary to highdose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97: 61-62.
3. Cancer chemotherapy and acral erythema. Ann Intern Med 1982; 97: 783-784.
4. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361-369.
5. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-799.
6. Nagore E, Insa A, Sanmartin O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-234.
7. Susser WS, Whitaker-Worth DL, Grant-Kels JM: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40: 367-398, quiz 399-400.
8. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
9. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70: 141-146.
10. Abushullaih S, Saad ED, Munsell M, Hoff PM: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20: 3-10.
11. Grandinetti CA, Goldspiel BR: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007; 27: 1125-1144.
12. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12: 191-200.
13. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
15. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
17. Gressett SM, Stanford BL, Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131-141.
18. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
19. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16: 3537-3541.
20. Demircay Z, Gurbuz O, Alpdogan TB, Yucelten D, Alpdogan O, Kurtkaya O, Bayik M: Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997; 36: 593-598.
21. Titgan MA: Palmar-plantar erythrodysesthesia associated with liposomal encapsulated doxorubicin (Doxil) by oral dexamethasone (abstract). Proc Am Soc Clin Oncol 1997; 16(suppl):288a.
22. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-2173.
23. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL: Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004; 94: 320-324.
24. Razis E, Karina M, Karanastassi S, Fountzilas G: Three case reports of hand-foot syndrome with gefitinib. Cancer Invest 2006; 24: 514-516.
25. Crider MK, Jansen J, Norins AL, McHale MS: Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986; 122: 1023-1027.
26. Doyle LA, Berg C, Bottino G, Chabner B: Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98: 611-612.
27. Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 2004; 44: 1166-1172.
28. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN: Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82: 965-969.
29. Jucgla A, Sais G, Navarro M, Peyri J: Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131: 364-365.
30. Jones AP, Crawford SM: Anthracycline-induced toxicity affecting palmar and plantar skin. Br J Cancer 1989; 59: 814.
31. Portal I, Cardenal F, Garcia-del-Muro X: Etoposide-related acral erythema. Cancer Chemother Pharmacol 1994; 34: 181.
32. Vassallo C, Passamonti F, Merante S, Ardigo M, Nolli G, Mangiacavalli S, Borroni G: Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001; 26: 141-148.
33. Wyatt AJ, Leonard GD, Sachs DL: Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7: 45-63.
34. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
35. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-762.
36. Amaravadi R, Schuchter LM, McDermott DF, Kramer A, Giles L, Troxel AB, Medina CA, Nathanson KL, O'Dwyer PJ, Flaherty KT: Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (abstract). J Clin Oncol 2007; 25(suppl):8527.
37. Bracarda S, Porta C, Boni C, Santoro A, Artioli F, Contu A, Mentuccia L, Gasparro D, Caserta C, De Angelis V: Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681 (abstract 357). San Francisco, American Society of Clinical Oncology Genitourinary Cancer Symposium, 2008.
38. D'Adamo DR, Keohan M, Undevia S, Livingston M, Cooney M, Kraft A, Saulle M, Schwartz GK, Maki RG: Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study 7060) (abstract 10001). J Clin Oncol 2008; 25 (suppl).
39. Eisen T, Marais R, Affolter A, Lorigan P, Ottensmeier C, Robert C, Corrie P, Chevreau C, Erlandsson F, Gore M: An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma (abstract 6044). J Clin Oncol 2007; 25(suppl).
40. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M: Phase II trial of single-agent sorafenib in patients with advanced nonsmall cell lung carcinoma (abstract 7002). J Clin Oncol 2006; 24(suppl).
41. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C: A phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET) (abstract 4504). J Clin Oncol 2007; 25(suppl).
42. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL: Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (abstract 4504). J Clin Oncol 2007; 25(suppl).
43. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
44. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-3301.
45. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-1485.
46. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results (abstract 5025). J Clin Oncol 2007; 25 (suppl).
47. Agarwala SS, Keilholz U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Patel K, Hauschild A: Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (abstract 8510). J Clin Oncol 2007; 25(suppl).
48. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
49. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-1887.
50. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
51. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-4799.
52. Srinivas S, Roigas J, Gillessen S, Harmenberg U, De Mulder PH, Fountzilas G, Vogelzang N, Peschel C, Flodgren P, Escudier B: Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results (abstract 5040). J Clin Oncol 2007; 25(suppl).
53. Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM: Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) (abstract 4522). J Clin Oncol 2006; 24(suppl).
54. George S, Blay JY, Casali PG, Le Cesne A, Morgan JA, Pokela J, Quigley MT, Tassell V, Baum CM, Demetri GD: Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST (abstract 10015). J Clin Oncol 2007; 25(suppl).
55. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Santoro A, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial) (abstract LBA1). J Clin Oncol 2007; 25(suppl).
56. Chu DT, Lacouture ME, Fillos T, Wu S: Risk of sorafenib-induced hand-foot skin reaction in patients with renal cell carcinoma and non-renal cell malignancy (abstract 3777). San Francisco, ASCO Genitourinary Cancer Symposium, 2008.
57. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi JC, Bycott KF, Liau KF, Dutcher JP: Axitinib (AG-013736;AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib (abstract 5032). J Clin Oncol 2007; 25(suppl).
58. Baack BR, Burgdorf WH: Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457-461.
59. Narasimhan P, Narasimhan S, Hitti IF, Rachita M: Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 2004; 73: 101-106.
60. Beard JS, Smith KJ, Skelton HG: Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol 1993; 29: 325-330.
61. Waltzer JF, Flowers FP: Bullous variant of chemotherapy-induced acral erythema. Arch Dermatol 1993; 129: 43-45.
62. Feizy V, Namazi MR, Barikbin B, Ehsani A: Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J 2003; 9: 14.
63. Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ: High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132: 590-591.
64. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW: Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158: 592-596.
65. Autier J, Escudier B, Wechsler J, Spatz A, Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-892.
66. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW: Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24: 5786-5788.
67. Chu D, Lacouture ME, Fillos T, Wu S: Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47: 176-186.
68. Porta C, Paglino C, Imarisio I, Bonomi L: Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-134.
69. Horwitz LJ, Dreizen S: Acral erythemas induced by chemotherapy and graft-versushost disease in adults with hematogenous malignancies. Cutis 1990; 46: 397-404.
70. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63.
71. Wilkes GM, Doyle D: Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 2005; 9: 103-106.
72. Scheithauer W, Blum J: Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004; 18: 1161-1168, 1173, discussion 1173-1176, 1181-1184.
73. Hahn O, Stadler W: Sorafenib. Curr Opin Oncol 2006; 18: 615-621.
74. Hilger RA, Kredtke S, Scheulen ME, Seeber S, Strumberg D: Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther 2004; 42: 648-649.
75. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
76. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426-437.
77. Kroll SS, Koller CA, Kaled S, Dreizen S: Chemotherapy-induced acral erythema: desquamating lesions involving the hands and feet. Ann Plast Surg 1989; 23: 263-265.
78. Walker IR, Wilson WE, Sauder DN, Benger AM, Browman G: Cytarabine-induced palmar-plantar erythema. Arch Dermatol 1985; 121: 1240-1241.
79. Baer MR, King LE, Wolff SN: Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 1985; 102: 556.
80. Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC, Hutchins KS: Pyridoxine treatment and prevention of hand-andfoot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 2003; 9: 161-166.
81. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
82. Curran CF, Luce JK: Fluorouracil and palmar-plantar erythrodysesthesia. Ann Intern Med 1989; 111: 858.
83. Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C: Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13: 1781-1783.
84. Keohan M, D'Adamo D, Qin L, Saulle M, Caltieri L, Schuetze S, Wright JJ, Schwartz G, Maki R: Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS) (abstract 10061). J Clin Oncol 2007; 25(suppl).
85. Kampmann KK, Graves T, Rogers SD: Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989; 63: 2482-2485.
86. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, Burock K, Zou D, Voliotis D, Guan Z: Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma (abstract 4509). J Clin Oncol 2008; 26(suppl).
87. Shall L, Lucas GS, Whittaker JA, Holt PJ: Painful red hands: a side-effect of leukaemia therapy. Br J Dermatol 1988; 119: 249-253.
88. Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, McCollough ML, Von Hoff DD: Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131: 202-206.
89. Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB: Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007; 12: 1178-1182.
90. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-1011.
91. Fitzpatrick JE: The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 1993; 20: 1-14.
92. Horn TD: Antineoplastic chemotherapy, sweat, and the skin. Arch Dermatol 1997; 133: 905-906.
93. Lai SE, Kuzel T, Lacouture ME: Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25: 341-343.
94. Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W, Lademann J: Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005; 16: 1210-1211.
95. Ferrero JM, Lassalle S, Mari M, Formento JL, Francoual M, Lacour JP, Etienne-Grimaldi MC, Hofman P, Milano G: Hand-foot syndrome (HFS) in patients receiving capecitabine: a pharmacological explanation (abstract 2019). J Clin Oncol 2006; 24(suppl).
96. Lin E, Morris J, Chau NK, et al: Celecoxib attenuated capecitabine induced hand-andfoot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (abstract 2364). Proc Am Soc Clin Oncol 2002; 21(suppl).
97. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-356.
98. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
99. Vukelja SJ, Baker WJ, Burris HA 3rd, Keeling JH, Von Hoff D: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432-1433.
100. Vukelja SJ, Lombardo FA, James WD, Weiss RB: Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111: 688-689.
101. Longfield V, Hasan E, Romie A: A retrospective evaluation of the use of pyridoxine in the prevention and treatment of palmarplantar erythrodysesthesia in capecitabine-treated cancer patients (abstract 11). Oncol Nurs Forum 2001; 28.
102. Beveridge RA, Kales AN, Binder RA, Miller JA, Virts SG: Pyridoxine (B6) and amelioration of hand/foot syndrome (abstract 393). Proc Am Soc Clin Oncol 1990; 9 (suppl).
103. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-1571.
104. Lin EH, Ayer G, Crane C, et al: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, ameliorated capecitabine (X) hand and foot syndrome (HFS) and enhanced survival in metastatic colorectal cancer (abstract 3584). J Clin Oncol 2004; 22(suppl).
105. Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA: Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 1994; 86: 557-558.
106. Molpus KL, Anderson LB, Craig CL, Puleo JG: The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 2004; 93: 513-516.
107. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E: Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008; 108: 332-335.
108. Kingsley EC: 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994; 120: 813.
109. Kollmannsberger C, Mayer F, Harstrick A, Honecker F, Vanhofer U, Oberhoff C, Kanz L, Bokemeyer C: Reduction of skin toxicity of pegylated liposomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine in patients with anthracycline-sensitive malignancies - a phase I/II trial (abstract 632P). Ann Oncol 2000; 11.
110. Brown J, Burck K, Black D, Collins C: Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991; 24: 1023-1025.
111. Cohen PR: Acral erythema: a clinical review. Cutis 1993; 51: 175-179.
112. Yucel I, Guzin G: Topical henna for capecitabine induced hand-foot syndrome. Invest New Drugs 2008; 26: 189-192.
113. Pendharkar D, Goyal H: Novel and effective management of capecitabine induced hand foot syndrome (abstract 8105). J Clin Oncol 2004; 22(suppl).
114. Kara IO, Sahin B, Erkisi M: Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006; 15: 414-424.
115. Lyass O, Lotem M, Edelmann D, Hubert A, Gabizon A: Protective effect of amifostine (AMF) on Doxil/Caelyx-induced palmarplantar erythrodysesthesia (PPE) in patients (pts) with advanced cancer (abstract 2148). Proc Am Soc Clin Oncol 2001; 20(suppl).
116. Yee S, Jeffers S: Prevention and management of Doxil-related side effects: basic strategies (abstract 281). Proc Am Soc Clin Oncol 1998; 17(suppl).
117. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
118. Chin SF, Tchen N, Oza AM, et al: Use of 'Bag Balm' as topical treatment of palmarplantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapy agents. Proc Am Soc Clin Oncol 2001; 20: 409a.
119. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305.